Drug profile · INN
neratinib
NERLYNX
neratinib (NERLYNX) is a receptor protein-tyrosine kinase erbb-2 inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01EH02
Patents linked 0
Pipeline programs 28
News articles 0
Drug details — neratinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 28
- Data quality
- 0.83
Quick answer
neratinib (NERLYNX) is a receptor protein-tyrosine kinase erbb-2 inhibitor.
Key facts
INN neratinib
Brand NERLYNX
Mechanism Receptor protein-tyrosine kinase erbB-2 inhibitor
Target Epidermal growth factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EH02
Mechanism of action
Receptor protein-tyrosine kinase erbB-2 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is neratinib?
neratinib (NERLYNX) is a receptor protein-tyrosine kinase erbb-2 inhibitor.
What is the brand name for neratinib?
NERLYNX is a marketed brand name for neratinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.